Sites of Action of Subtoxic Doses of the Iodine-Containing X-Ray Contrast Medium Iopromide on the Kidney and the Search for Means of Preventing the Development of Nephropathy
- Authors: Sukoyan G.V.1, Kezeli T.D.2, Dolidze N.M.1, Fedorova M.M.3, Golovach V.V.1, Shimanovskii N.L.4
-
Affiliations:
- International Scientific Center for the Development and Introduction of Biomedical Technologies
- I. Dzhavakhishvili Tbilisi State University Tbilisi
- Russian Medical Academy of Postgraduate Education, Ministry of Health of the Russian Federation
- N. I. Pirogov Russian National Medical Research University
- Issue: Vol 51, No 9 (2017)
- Pages: 818-823
- Section: Drugs
- URL: https://journals.rcsi.science/0091-150X/article/view/244816
- DOI: https://doi.org/10.1007/s11094-017-1699-8
- ID: 244816
Cite item
Abstract
A controlled, randomized study using an experimental model of contrast (iopromide)-induced nephropathy (CIN) in normal mongrel rats showed that the combination of treatment by hydration with the nicotinamide adenine dinucleotide (NAD)-containing formulation Nadcin®, with cytoprotective and antiischemic actions, decreased the plasma creatinine and urea nitrogen levels 72 h after induction of CIN. Aclose correlational relationship (r = 0.78, p < 0.001) was found between the blood endothelin-1 (ET-1) level and O2– generation, while there was no relationship between hydrogen peroxide production and the ET-1 level (r = 0.13, p > 0.05) or between the ET-1 level and catalase activity (r = 0.41, p > 0.05). In contrast to monotherapy with hydration, inclusion of Nadcin normalized blood ET-1 and the blood ET-1/creatinine ratio, the blood and renal NAD/NADH and NADP/NADPH redox potentials, and had more marked actions on reversing the overproduction of free radicals and on the antioxidant defense system in the blood and renal tissue. It is suggested that ET-1, the ET-1/creatinine ratio, and the plasma redox potential can be used as early markers for increases in the risk of developing stable impairment of renal function on use of x-ray contract agents.
About the authors
G. V. Sukoyan
International Scientific Center for the Development and Introduction of Biomedical Technologies
Email: chem@folium.ru
Georgia, Tbilisi
T. D. Kezeli
I. Dzhavakhishvili Tbilisi State University Tbilisi
Email: chem@folium.ru
Georgia, Tbilisi
N. M. Dolidze
International Scientific Center for the Development and Introduction of Biomedical Technologies
Email: chem@folium.ru
Georgia, Tbilisi
M. M. Fedorova
Russian Medical Academy of Postgraduate Education, Ministry of Health of the Russian Federation
Email: chem@folium.ru
Russian Federation, Moscow
V. V. Golovach
International Scientific Center for the Development and Introduction of Biomedical Technologies
Email: chem@folium.ru
Georgia, Tbilisi
N. L. Shimanovskii
N. I. Pirogov Russian National Medical Research University
Email: chem@folium.ru
Russian Federation, Moscow